Bayo J, et al. – A blood biomarker with levels that exceeded the normal range established in the general population that could be used to screen breast cancer was searched by this study. For screening early stage breast cancer, data emphasised 8–OHdG as a new potential marker. This study built a model that combined five blood markers that could be used as a diagnostic test in certain groups of patients.

Methods

• In this case–control study, clinicians investigated conventional as well as research (NGAL, EGFR and 8-OHdG) tumor biomarkers.

Results

• This study incorporated a total of 126 women (cases: 63 patients with local breast cancer; Controls: 63 healthy women).
• Findings highlighted significant differences in patients with higher levels of the conventional markers, Ca15.3, CEA, Cyfra 21.1 and NSE.
• Only Ca 15.13 was significant, when commercial cut-off values were used.
• Significantly higher levels of EGFR were found in the control group, and of 8-OHdG in the case group, in the group of research biomarkers.
• Using logistic regression analysis and a ROC curve, they acquired an equation composed of five markers, Ca 15.3, NSE, NGAL, EGFR and 8-OHdG, which yielded a correct diagnostic probability of breast cancer of 91.8%.